Skip to content
Search

Latest Stories

Ketan Mehta’s TV series Captain Vyom to be made into five-part film

Murtuza Iqbal

A few days ago, Mukesh Khanna had announced that they will be making a three-part film on the popular TV series Shaktimaan, and now, the makers of Milind Soman starrer Captain Vyom are all set to adapt the TV series for the big screen.


A source stated, "The new-age adaptations, in the form of web shows and film series, will show the never-seen-before world in the sci-fi space, to Indian audiences. One of the top young Bollywood stars is in talks with the makers to play the lead character. If all goes well, work on the first film of the series will begin by mid-2021. Initially, makers had planned to start work on the film series in 2020 itself but Covid-19 delayed their plans."

Confirming the news, the director of the series, Ketan Mehta said, "When we created India’s first sci-fi TV series (the first episode aired in 1998) in the form of Captain Vyom, it inspired a whole generation of kids at the turn of the century. Now, with India entering the space age, I am glad that Captain Vyom is being reinvented for the new age as a big-screen spectacle, and the web space, with cutting-edge visual effects, for a global audience."

"Captain Vyom, an intergalactic space adventure with a unique Indian perspective, can showcase the best of VFX and CGI talent of the country. Here's raising a toast to Captain Vyom and new India,” the filmmaker added.

Milind Soman as Captain Vyom had impressed one and all. Now, let’s wait and watch which actor will play the lead role on the big screen.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less